Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Alzheimer's
New Beckman Coulter biomarker immunoassays support Alzheimer's research
By
LabPulse.com staff writers
Beckman Coulter Diagnostics has announced the availability of new research-use-only blood-based biomarker immunoassays designed to advance neurodegenerative disease research.
January 15, 2025
Veravas, Phanes Biotech to collaborate on Alzheimer's tau pathology assay
By
LabPulse.com staff writers
Clinical diagnostics developer Veravas and Phanes Biotech have announced that they will co-develop a blood-based Alzheimer’s disease (AD) tau pathology test.
November 8, 2024
Alzheimer's panel validated in University of Pittsburgh study
By
LabPulse.com staff writers
A team at the University of Pittsburgh has validated a new blood test panel that can simultaneously measure over 100 Alzheimer's disease biomarkers.
November 4, 2024
C2N, Unilabs sign global agreement on early Alzheimer's diagnostics
By
LabPulse.com staff writers
C2N and Unilabs have signed a multiyear agreement that will increase access to C2N's Precivity blood tests for the early diagnosis of Alzheimer's disease to Unilabs' testing network on an exclusive basis.
August 8, 2024
ALZpath, Roche sign licensing agreement for dementia biomarker
By
LabPulse.com staff writers
ALZpath has signed a licensing agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize a diagnostic blood test for Alzheimer's disease that will be offered on the Roche Elecsys platform.
June 12, 2024
Quest adds new biomarker test to Alzheimer's portfolio
By
LabPulse.com staff writers
Quest Diagnostics has launched a new blood biomarker test as part of its AD-Detect portfolio of blood tests for Alzheimer's disease risk assessment.
April 23, 2024
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
By
LabPulse.com staff writers
The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).
April 11, 2024
FDA updates draft guidance for Alzheimer's drug development biomarkers
By
LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has released an updated draft guidance for the use of biomarkers aimed at sponsors and pharmaceutical companies developing drugs intended to treat early Alzheimer's disease.
March 14, 2024
Eisai invests $15M in C2N to increase Alzheimer's test access
By
LabPulse.com staff writers
C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.
March 6, 2024
Alzheimer’s study results show correlation between blood-based biomarkers and amyloid plaques
By
LabPulse.com staff writers
The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer's disease (AD).
March 1, 2024
NHS lacks capacity for Alzheimer’s diagnostics, warn experts
By
Matt Limb
Many thousands of patients in the U.K. could miss out on new treatments for Alzheimer’s disease because its National Health Service (NHS) lacks capacity for diagnostic tests, warn experts.
February 14, 2024
Blood test for Alzheimer’s shows high accuracy in study
By
Matt Limb
Scientists have hailed study results showing the high accuracy of a blood test that “could revolutionize” diagnosis of Alzheimer’s disease.
January 31, 2024
Page 1 of 8
Next Page
